BioRestorative Therapies (FRA:9OF) Moat Score: 2/10 (As of Jul. 01, 2026)


FRA:9OF BioRestorative Therapies Inc FRA:9OF
51 GF Score
Price €0.31
GF Value €1.26
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioRestorative Therapies Moat Score?

BioRestorative Therapies FRA:9OF -3.68% 51 Moat Score is 2 as of Jul. 01, 2026. GuruFocus rates FRA:9OF with a GF Score™ of 51/100 and a GF Value™ of €1.26 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,400 Biotechnology companies, BioRestorative Therapies ranks better than 58.07% on this metric.

BioRestorative Therapies has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

BioRestorative Therapies has No Moat: BioRestorative Therapies has very weak competitive advantages. It operates in a highly competitive biotech sector with limited market share and lacks significant intellectual property or regulatory barriers. The company does not exhibit strong brand strength or customer loyalty, resulting in a low moat score.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioRestorative Therapies might have No Moat - Very weak/transient advantages.

BioRestorative Therapies  (FRA:9OF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioRestorative Therapies Moat Score Related Terms

FRA:9OF vs CVKD, JSPR, APRE: Moat Score Comparison

For the Biotechnology subindustry, BioRestorative Therapies's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRestorative Therapies Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Moat Score distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Moat Score falls into.


FRA:9OF
51GF Score
BioRestorative Therapies Inc FRA:9OF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
BioRestorative Therapies (FRA:9OF) has a Moat Score of 2 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BioRestorative Therapies ranks #587 out of 1400 companies in the Biotechnology industry, placing it in the top 41.9%.
Is BioRestorative Therapies' Moat Score too high?
BioRestorative Therapies' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. BioRestorative Therapies' value of 2 is 0% at this industry median. Based on the distribution chart, BioRestorative Therapies ranks #587 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioRestorative Therapies has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Moat Score compare to CVKD and JSPR?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #587 out of 1400 companies for Moat Score. This puts BioRestorative Therapies in the upper half of its industry. The industry median Moat Score is 2.00. BioRestorative Therapies' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRestorative Therapies's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.26, compared to a current price of €0.31 — trading 75.1% below its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. BioRestorative Therapies' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current Moat Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?

Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued. The current stock price of €0.31 is trading 75.1% below its estimated GF Value™ of €1.26. GuruFocus considers BioRestorative Therapies to be Possible Value Trap.

Key valuation signals for FRA:9OF:

  • Moat Score: 2
  • GF Value™: €1.26 vs. price of €0.31 (75.1% below fair value)
  • GF Score™: 51/100 with 3 warning signs
  • Industry Position: 0% at the Biotechnology median (#587 of 1400)

No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioRestorative Therapies Business Description

Other Exchanges BRTX:USA
Address 40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score

Get the complete analysis for FRA:9OF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.31
Price
€1.26
GF Value